Oculis Holding Says Phase 2 Trial of Acute Optic Neuritis Therapy Met Primary Safety Endpoint

MT Newswires Live

2025/01/06

Oculis Holding (OCS) said Monday a phase 2 trial evaluating OCS-05 in patients with acute optic neuritis met the primary endpoint of safety and achieved statistical significance on several efficacy-based secondary endpoints.

Acute optic neuritis is a condition characterized by inflammation of the optic nerve that can results in permanent visual impairment.

The trial highlighted "neuroprotective structural benefit and the ability to improve visual function in patients suffering from acute optic neuritis," the company said.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2501286604"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501286604\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501286604?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-06 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501286604","market":"us","top_or_hot":-1,"title":"Oculis Holding Says Phase 2 Trial of Acute Optic Neuritis Therapy Met Primary Safety Endpoint","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OCS\">Oculis</a> Holding (OCS) said Monday a phase 2 trial evaluating OCS-05 in patients with acute optic neuritis met the primary endpoint of safety and achieved statistical significance on several efficacy-based secondary endpoints.</p><p>Acute optic neuritis is a condition characterized by inflammation of the optic nerve that can results in permanent visual impairment.</p><p>The trial highlighted \"neuroprotective structural benefit and the ability to improve visual function in patients suffering from acute optic neuritis,\" the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oculis Holding Says Phase 2 Trial of Acute Optic Neuritis Therapy Met Primary Safety Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOculis Holding Says Phase 2 Trial of Acute Optic Neuritis Therapy Met Primary Safety Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-06 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OCS\">Oculis</a> Holding (OCS) said Monday a phase 2 trial evaluating OCS-05 in patients with acute optic neuritis met the primary endpoint of safety and achieved statistical significance on several efficacy-based secondary endpoints.</p><p>Acute optic neuritis is a condition characterized by inflammation of the optic nerve that can results in permanent visual impairment.</p><p>The trial highlighted \"neuroprotective structural benefit and the ability to improve visual function in patients suffering from acute optic neuritis,\" the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2501286604","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501286604","pubTimestamp":1736157662,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Oculis Holding  said Monday a phase 2 trial evaluating OCS-05 in patients with acute optic neuritis met the primary endpoint of safety and achieved statistical significance on several efficacy-based secondary endpoints.Acute optic neuritis is a condition characterized by inflammation of the optic nerve that can results in permanent visual impairment.The trial highlighted \"neuroprotective structural benefit and the ability to improve visual function in patients suffering from acute optic neuritis,\" the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OCS":"Oculis"},"translate_title":"Oculis Holding表示急性视神经炎治疗的2期试验达到了主要安全终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCS":1},"content_text":"Oculis Holding (OCS) said Monday a phase 2 trial evaluating OCS-05 in patients with acute optic neuritis met the primary endpoint of safety and achieved statistical significance on several efficacy-based secondary endpoints.Acute optic neuritis is a condition characterized by inflammation of the optic nerve that can results in permanent visual impairment.The trial highlighted \"neuroprotective structural benefit and the ability to improve visual function in patients suffering from acute optic neuritis,\" the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}